A secondary aim was to compare the clinical features and insulin treatment sequelae/requirements between the first and second wave of SARS-CoV-2 infection (December 2020–January 2021) in people with T2DM who required insulin as a new treatment. Here, INS is linked to type 2 diabetes mellitus.